Combination Analysis of NR3C1, MTHFR and IGFBP3 Gene Polymorphisms and DNA Methylation With Steroid-induced Osteonecrosis of the Femoral Head Risk in Chinese Han Population

Ronglan Huang  
Anhui University of Traditional Chinese Medicine

Qinghao Zhan  
Anhui University of Traditional Chinese Medicine

Wenbin Hu (✉ hwbzhx@163.com)  
Anhui University of Traditional Chinese Medicine https://orcid.org/0000-0002-4452-7176

Renmin Yang  
Anhui University of Traditional Chinese Medicine

Nan Cheng  
Anhui University of Traditional Chinese Medicine

Yongsheng Han  
Anhui University of Traditional Chinese Medicine

Technical advance

Keywords: NR3C1, MTHFR, IGFBP3, ONFH, Polymorphisms, DNA methylation

DOI: https://doi.org/10.21203/rs.3.rs-87796/v1

License: ©️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** Although the precise etiology of osteonecrosis of the femoral head (ONFH) has yet to be fully elucidated, it is known that nuclear receptor subfamily3, group C, member 1 (NR3C1), 5, 10-methylenetetrahydrofolate reductase (MTHFR) and insulin-like growth factor-binding protein 3 (IGFBP3) are related to the pathophysiology of steroid-induced osteonecrosis of the femoral head (SONFH). The expression of NR3C1, MTHFR and IGFBP3 are regulated by epigenetics and genetic profiles.

**Objective:** The primary objective of this study was to investigated the association between NR3C1, MTHFR and IGFBP3 gene polymorphisms and DNA methylation status and SONFH.

**Methods:** This case-control study included 79 patients with SONFH and 114 patients who took steroids but did not develop SONFH. We evaluated 5 single-nucleotide polymorphisms (SNPs) out of 3 genes in Chinese Han population. These SNPs were genotyped by improved multiplex ligation detection reaction (iMLDR). Methyltarget was used to test the methylation level of positive sites, the interaction between SNPs and DNA methylation level was analyzed using eQTLD technique.

**Results:** We identified rs3110697 in the IGFBP3 gene that was potentially associated with a reduced risk of SONFH in the genotype (P=0.008; odds ratio [OR]: 0.741; 95% confidence intervals [CI]: 0.456–1.205) and in the recessive model (P=0.003; OR: NA; 95% CI: NA–NA). Furthermore, CpG sites with significant differences in methylation levels were screened as follows: IGFBP3_2-139, MTHFR_1-36, MTHFR_1-77, MTHFR_1-139, MTHFR_2-42, NR3C1_2-163, NR3C1_4-47, and the differences were statistically significant compared with the control group (p<0.05). A total of 10 pairs of linear regression tests of SNP and methylation sites were statistically significant (p<0.05).

**Conclusions:** SONFH is a polygenic disorder in which a wide range of interactions between SNPs and DNA methylation levels may dominate the course of the disease.

Introduction

Although osteonecrosis of the femoral head (ONFH) is an orthopedic disease, it is also a complication of multiple disciplines. Due to the interruption of blood supply to the femoral head, bone cell apoptosis and changes in the microstructure of the femoral head were induced, resulting in the presence of femoral head pain and progressive aggravation. Clinical and epidemiological studies have identified excessive alcohol consumption and the use of high-dose corticosteroids as the two most important causes of non-traumatic ONFH (Cui et al. 2016). In recent years, association studies based on candidate genes have successfully located susceptibility to many complex diseases (Uitto et al. 2019; Wan 2018). Some genetic background has been shown to be associated with ONFH in previous studies. In clinical practice, we can find that not all patients with steroid hormones use develop SONFH, suggesting that genetic factors may influence SONFH susceptibility or drug resistance (Hadjigeorgiou et al. 2009). In addition to gene sequence differences, gene expression and function are also regulated by epigenetic regulation, and DNA methylation is one of the most in-depth epigenetic modifications. Studying the genetic etiology of SONFH will help us to understand the biological and physiological mechanisms of SONFH and provide a basis for individualized treatment of SONFH.

Current evidence suggests that 5 SNPs of the 3 genes we studied are associated with SONFH and can be identified by genome-wide association studies. Nuclear receptor subfamily3, group C, member 1 (NR3C1) is an important transcriptional regulator that mediates the role of glucocorticoids. There are many mutations and polymorphisms, which affect the sensitivity of individuals to exogenous glucocorticoids (Nordkap et al. 2017). BClI (rs41423247) polymorphism of NR3C1 gene is a relatively common polymorphism variant and has been reported to be associated with hypertension and increased glucocorticoid sensitivity (Ukkola et al. 2001; Rosmond et al. 2000). NR3C1 rs6196 A allele carriers had a higher risk of steroid resistance than G allele carriers. Compared with G allele, the presence of rs10052957 and rs258751 A alleles reduced the incidence of steroid resistance (Liu et al. 2018). Some genetic background has been shown to be associated with ONFH in previous studies. In clinical practice, we can find that not all patients with steroid hormones use develop SONFH, suggesting that genetic factors may influence SONFH susceptibility or drug resistance (Hadjigeorgiou et al. 2009). In addition to gene sequence differences, gene expression and function are also regulated by epigenetic regulation, and DNA methylation is one of the most in-depth epigenetic modifications. Studying the genetic etiology of SONFH will help us to understand the biological and physiological mechanisms of SONFH and provide a basis for individualized treatment of SONFH.
competitive binding with ligands. IGF1 regulates the proliferation and differentiation of osteoblast through autocrine and paracrine (Feng et al. 2014). Norihiro Kato et al. (2015) proved that the SNPs of IGFBP3 gene affecting blood pressure were related to the methylation of multiple CpG sites. It further suggests that DNA methylation may play a broader role in associating common genetic variations with multiple phenotypes.

A few studies have investigated NR3C1, MTHFR and IGFBP3 gene polymorphisms and DNA methylation with the pathogenesis of SONFH. We hypothesized that NR3C1, MTHFR and IGFBP3 genes play a key role in the occurrence of SONFH, and explored the relationship between the polymorphism and DNA methylation of these genes and SONFH in Chinese Han population.

Materials And Methods

Study participants

The 79 SONFH patients were derived from the Affiliated Hospital of the Institute of Neurology of Anhui University of Chinese Medicine and the First Affiliated Hospital of the Anhui University of Traditional Chinese Medicine from July 2017 to February 2019. These SONFH patients were treated with standard steroids after being diagnosed with Devic's disease, chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, or rheumatoid arthritis. Patients with traumatic ONFH, other hip joint disorders, and patients not conforming to the diagnosis of SONFH were excluded.

According to the medical examination of the Affiliated Hospital of the Institute of Neurology of Anhui University of Chinese Medicine, we recruited 114 patients who had not suffered from femoral head necrosis for more than 3 years after 3 months of oral steroid hormone (prednisone > 30 mg/d) treatment as the control group from June 2017 to February 2019. All participants were limited to the Han Chinese population living in and around Hefei. This study protocol was approved by the ethics committee of the Affiliated Hospital of the Institute of Neurology of Anhui University of Chinese Medicine and obtained the written informed consent of all participants or their guardians.

Genotyping

The genomic DNA was extracted using a Wizard Genomic DNA Purification Kit (Promega, Madison, Wisconsin, USA) as per the product instruction. The SNP genotyping work was performed using an improved multiplex ligation detection reaction (iMLDR) technique developed by Genesky Biotechnologies Inc. (Shanghai, China). A multiplex PCR-ligase detection reaction method was used in the iMLDR. For each SNP, the alleles were distinguished by different fluorescent labels of allele-specific oligonucleotide probe pairs.

Cpg Islands Selected

CpG islands located in the proximal promoter of NR3C1, MTHFR and IGFBP3 gene were selected for measurement according to the following criteria: (1) 200 bp minimum length; (2) 50% or higher GC content; (3) 0.60 or higher ratio of observed/expected dinucleotides CpG. Finally, six CpG islands regions of NR3C1, MTHFR and IGFBP3 gene were selected and sequencing.

DNA Methylation Detection

Bisulfite conversion of 400 ng genomic DNA was conducted using the EZ DNA Methylation™-GOLD Kit (ZYMO RESEARCH, CA, USA). Firstly, the samples with the rate of DNA bisulfite conversion < 98% were filtered out. PCR amplicons of target CpG regions were separated by agarose electrophoresis and purified using QIAquick Gel Extraction kit (QIAGEN, Hilden, Germany), and CpG sites methylation assay was performed using Illumina Hiseq 2500 according to the manufacturer's protocol. The methylation level of the IL12B gene was analyzed by MethylTarget™ (Genesky Biotechnologies Inc., Shanghai, China). The details of the CpG regions are listed in Table 5.

Statistical analysis

SPSS 24.0 (SPSS, Chicago, IL) was used for statistical analysis. The allele distribution was tested for Hardy-Weinberg equilibrium (HWE) by \( \chi^2 \). The ORs and 95% CI was determined by unconditional logistic regression analysis. Significant results were defined if \( p \) value was less than 0.05. Haploview (Chicago, IL) (https://sourceforge.net/projects/haploview/) were used to analyze the linkage imbalance of different SNPs within the same genus.

Results
The analysis included 79 cases (34 males, 45 females; mean age 50.65 ± 13.95 years) who were SONFH patients and 114 controls (49 males, 65 females; mean age 42.63 ± 19.27 years) who received steroid therapy but did not develop SONFH. The demographic characteristics of patients and control subjects are illustrated in Table 1.

### Table 1

| Characteristics | SONFH (n = 79) | Controls (n = 114) | t value | P value |
|-----------------|---------------|-------------------|---------|---------|
| Age             | 50.65 ± 13.95 | 42.63 ± 19.27     | 3.3305  | 0.001   |
| Gender          | Female 45, Male 34 | Female 65, Male 49 | 0.1273  | 0.8989  |

We selected 5 SNPs (rs10052957 and rs41423247 of NR3C1 gene, rs1801133 of MTHFR gene, rs2453839 and rs3110697 of IGFBP3 gene) were genotyped by iMLDR. SNP ID, gene, location, allele, minor allele frequency (MAF) and P value of HWE for 5 SNPs are shown in Table 2. All 5 selected SNPs passed the HWE test. As listed in Table 3. We identified one significant SNP, rs3110697 (P = 0.008; OR: 0.7411; 95% CI: 0.456–1.205), as being associated with the disease status of SONFH. The genotype “A/G” of rs3110697 is a protective genotype. Meanwhile, we found that rs3110697 in the IGFBP3 gene was associated with SONFH as a protective factor in the allele model (P = 0.003; OR: NA; 95% CI: NA–NA) (Table 4).

### Table 2

| SNP ID  | Gene   | Location(GRCh37) | Allele | MAF   | P value of HWE |
|---------|--------|------------------|--------|-------|----------------|
| rs10052957 | NR3C1 | chr5:142786701  | A/G | 0.115385 | 1 |
| rs41423247 | NR3C1 | chr5:142778575  | C/G | 0.237981 | 0.2351 |
| rs1801133  | MTHFR | chr1:11856378   | G/A  | 0.375  | 0.5665 |
| rs2453839  | IGFBP3| chr7:45953573   | C/T  | 0.216346 | 0.4604 |
| rs3110697  | IGFBP3| chr7:45955029   | A/G  | 0.747596 | 0.2785 |
Table 3
Analyses of association of allele and genotype frequency with the risk of SONFH between controls and patients with SONFH

| SNP ID     | Allele | SONFH | Controls | OR (95%CI)       | P value | genotype | SONFH | Controls | OR (95%CI)       | P value |
|------------|--------|-------|----------|------------------|---------|----------|-------|----------|------------------|---------|
| rs10052957 | A      | 25    | 27       | 1.443(0.802–2.595) | 0.221   | AA       | 2     | 1        | 1.458(0.802–2.652) | 0.377   |
|            | G      | 129   | 201      |                  |         | AG       | 21    | 25       |                 |         |
|            |        |       |          |                  |         | GG       | 54    | 88       |                 |         |
| rs41423247 | C      | 36    | 56       | 0.906(0.561–1.463) | 0.687   | CC       | 2     | 9        | 0.913(0.577–1.446) | 0.946   |
|            | G      | 122   | 172      |                  |         | CG       | 26    | 38       |                 |         |
|            |        |       |          |                  |         | GG       | 48    | 67       |                 |         |
| rs1801133  | G      | 83    | 108      | 1.23(0.819–1.846)  | 0.319   | GG       | 20    | 25       | 1.243(0.818–1.888) | 0.524   |
|            | A      | 75    | 120      |                  |         | GA       | 43    | 58       |                 |         |
|            |        |       |          |                  |         | AA       | 16    | 31       |                 |         |
| rs2453839  | C      | 36    | 65       | 0.731(0.456–1.17)  | 0.191   | CC       | 5     | 9        | 0.788(0.254–2.448) | 0.783   |
|            | T      | 122   | 161      |                  |         | CT       | 30    | 49       |                 |         |
|            |        |       |          |                  |         | TT       | 46    | 56       |                 |         |
| rs3110697  | A      | 38    | 67       | 0.761(0.479–1.209) | 0.247   | AA       | 0     | 11       | 0.715(0.439–1.165) | 0.428   |
|            | G      | 120   | 161      |                  |         | AG       | 38    | 45       |                 |         |
|            |        |       |          |                  |         | GG       | 41    | 58       |                 |         |

Table 4
Genetic model analyses of association between controls and patients with SONFH

| SNP ID     | Recessive Model | SONFH | Controls | OR(95%CI) | P value | Dominant Model | SONFH | Controls | OR(95%CI) | P value |
|------------|-----------------|-------|----------|-----------|---------|----------------|-------|----------|-----------|---------|
| rs10052957 | AA              | 2     | 1        | 3.013(0.268–33.820) | 0.566   | AA + AG       | 22    | 26       | 1.281(0.645–2.543) | 0.480   |
|            | AG + GG         | 75    | 113      |           |         | GG            | 52    | 82       |           |         |
| rs41423247 | CC              | 5     | 9        | 0.788(0.254–2.448) | 0.783   | CC + CG       | 29    | 46       | 0.745(0.400–1.388) | 0.354   |
|            | CG + GG         | 74    | 105      |           |         | GG            | 47    | 62       |           |         |
| rs1801133  | GG              | 20    | 25       | 1.207(0.615–2.367) | 0.607   | GG + GA       | 60    | 79       | 1.420(0.692–2.914) | 0.339   |
|            | GA + AA         | 59    | 89       |           |         | AA            | 16    | 29       |           |         |
| rs2453839  | CC              | 3     | 8        | 0.518(0.133–2.017) | 0.530   | CC + CT       | 32    | 54       | 0.717(0.39–1.319)  | 0.285   |
|            | CT + TT         | 76    | 105      |           |         | TT            | 44    | 53       |           |         |
| rs3110697  | AA              | 0     | 11       | NA(NA-NA) | 0.003*  | AA + AG       | 36    | 52       | 1.056(0.576–1.936) | 0.861   |
|            | AG + GG         | 79    | 103      |           |         | GG            | 40    | 56       |           |         |
Table 5
The position of the two CpG regions and primer sequences

| Target     | Location(GRCh37)        | Length | Primer sequences                        |
|------------|-------------------------|--------|-----------------------------------------|
| IGFBP3_1   | chr7::45961336−45961138 | 199    | GGAATTAATTTGAAAGTTTTTAYGAGGT            |
|            |                         |        | CACTCCAAACCACCTCAACAC                   |
| IGFBP3_2   | chr7::45960153–45960353 | 201    | TYGGTTGGGAGGGGTTTTTT                   |
|            |                         |        | AACRCCRCACACTCAGAATTAAAC               |
| IGFBP3_3   | chr7::45960753–45960920 | 168    | GGGGTAYGTTTGTGGGTAGTT                  |
|            |                         |        | CCTAAACCCCCACTTCTCT                   |
| MTHFR_1    | chr1::11866211−11865947 | 265    | GGATTGAGATTAGGTTGGTTGT                 |
|            |                         |        | TCCAATCCCRAATACACACACAC              |
| MTHFR_2    | chr1::11865629−11865376 | 254    | ATTTAGTGATTGTGGGTAGTTGT                 |
|            |                         |        | TCTCTCAAAATAAACCTCAGA                    |
| NR3C1_1    | chr5::142785050−142784881 | 170   | GYGAATTTTTTGTAGATGTTGTG                |
|            |                         |        | CCACAACCACCTCTCCTACCTC                  |
| NR3C1_2    | chr5::142783157−142782953 | 205  | TTTTTTTTTTGAGTTTGTGTGGT                |
|            |                         |        | AATCTCCATTACCAACTAACCAC                 |
| NR3C1_3    | chr5::142783652–142783828 | 177  | ATYYGGAAGTGYTTTTGTGTTGT                |
|            |                         |        | CAACCCCRATACCCCTTC                    |
| NR3C1_4    | chr5::142782574–142782730 | 157  | GGAGGGAGGAGAAGAGGTTAG                  |
|            |                         |        | AAATACCRCTAAAAACCHARAACAACCTC           |

Haploview software was used to analyze the linkage imbalance of NR3C1 gene SNPs (rs41423247 and rs10052957) and IGFBP3 gene SNPs (rs2453839 and rs3110697), and it was found that there was no strong linkage between SNPs.

In addition, we screened the CpG islands of NR3C1, MTHFR and IGFBP3 genes, looking for the CpG islands in the region from upstream 2K to downstream 1K of the first exon (including all shear modes) of the gene transcription initiation site. Primer3(http://primer3.ut.ee/)software was also used to design primers for Bisulfite treated sequences (Table 5). In this study, a total of 164 CpG sites were detected, and the differences in methylation levels at each CpG site were tested for significance. The CpG sites with significant differences in methylation levels were screened out as follows: IGFBP3_2-143, MTHFR_1–36, MTHFR_1–77, MTHFR_1-139, MTHFR_2–42, NR3C1_2-163, NR3C1_4–47 (Table 6). Further, quantitative trait loci (QTL) mapping method was used to jointly analyze the SNP typing results of all samples and the methylation level of the corresponding methylation sites, and a total of 10 pairs of linear regression tests between SNPs and methylation sites were conducted with P < 0.05, which was statistically significant (Table 7).

Table 6
Differences of methylation levels of sites, targets and gene

| Target     | Position | Type | SONFH (mean ± SD) | Controls (mean ± SD) | OR(L95-U95) | P-value |
|------------|----------|------|------------------|----------------------|-------------|---------|
| IGFBP3_2   | 143      | CG   | 6.2 ± 2.5        | 5.3 ± 1.8            | 1.207(1.024–1.423) | 0.025   |
| MTHFR_1    | 36       | CG   | 0.5 ± 0.3        | 0.6 ± 0.3            | 0.260(0.077–0.879) | 0.030   |
| MTHFR_1    | 77       | CG   | 0.4 ± 0.3        | 0.5 ± 0.3            | 0.257(0.068–0.963) | 0.044   |
| MTHFR_1    | 139      | CG   | 0.7 ± 0.4        | 0.9 ± 0.4            | 0.286(0.108–0.759) | 0.012   |
| MTHFR_2    | 42       | CG   | 0.9 ± 0.3        | 0.8 ± 0.3            | 3.679(1.00-13.511) | 0.049   |
| NR3C1_2    | 163      | CG   | 1.0 ± 0.3        | 1.1 ± 0.3            | 0.265(0.078–0.895) | 0.032   |
| NR3C1_4    | 47       | CG   | 0.6 ± 0.2        | 0.6 ± 0.2            | 0.140(0.024–0.813) | 0.028   |
Table 7
 meQTL analysis between SNP and CpG loci

| SNP         | gene          | beta     | t-stat   | p-value |
|-------------|---------------|----------|----------|---------|
| rs3110697   | IGFBP3_2-106 | 0.003685037 | 2.691716501 | 0.008 |
| rs2453839   | IGFBP3_2-171 | 0.007416736 | 2.601485177 | 0.010 |
| rs10052957  | NR3C1_1-68   | -0.000705172 | -2.220407393 | 0.028 |
| rs10052957  | NR3C1_1-144  | -0.000943779 | -2.241099197 | 0.027 |
| rs10052957  | NR3C1_3-65   | -0.000817371 | -2.916176834 | 0.004 |
| rs10052957  | NR3C1_3-51   | 0.00057689  | 2.47573142  | 0.014 |
| rs10052957  | NR3C1_4-32   | -0.001172311 | -2.38633154  | 0.018 |
| rs10052957  | NR3C1_4-91   | 0.000697272 | 2.100263333 | 0.037 |
| rs1801133   | MTHFR_1-202  | 0.000965155 | 2.077630625 | 0.040 |
| rs1801133   | MTHFR_2-85   | -0.000579351 | -2.660524526 | 0.009 |

**Discussion**

ONFH is a disease characterized by necrosis of one or more parts of the femoral head. ONFH can cause severe joint pain and limited physical activity, and some severe cases even require surgical intervention to restore normal function (Werner et al. 2003). Steroids are widely used in clinical practice. However, in recent years, steroids have become the leading cause of non-traumatic ONFH (Kerachian et al. 2009). We hope to find the genetic and epigenetic links between several important genes related to SONFH through the study of gene polymorphisms and DNA methylation.

In our case-to-case study, we did not find a relationship between rs10052957 and rs41423247 in NR3C1 gene and SONFH risk. However, in the further study of DNA methylation, compared with the control group, we screened for the first time the CpG sites of NR3C1_2-163 and NR3C1_4-47 with significant differences in methylation levels, and found that there was a correlation between NR3C1 gene SNPs and DNA methylation. According to previous researches, glucocorticoid is an important regulator of energy homeostasis. Most effects of glucocorticoids are mediated by the glucocorticoid receptor (Nicolai et al. 2010). Glucocorticoid receptor is composed of DNA-binding domain, hormone binding domain and amino terminal region, and plays a decisive role in glucocorticoid sensitivity (Bamberger et al. 1995). Any of these changes in the molecular mechanisms of glucocorticoid receptor action can alter tissue sensitivity to glucocorticoid, possibly leading to drug resistance or allergy, and serious complications. NR3C1 polymorphisms are associated with changes in glucocorticoid sensitivity, body composition, and metabolic parameters. The polymorphism of rs41423247 is the change of C → G nucleotide downstream of the connection region of intron 2 of exon 2 of glucocorticoid receptor gene (van Rossum and Lamberts 2004). Rs41423247 polymorphism is associated with changes in susceptibility to exogenous glucocorticoid in rheumatoid arthritis and healthy individuals (van Rossum et al. 2003; Derijk et al. 2001). Yan et al. (2013) reported that in rs10052957, A allele carriers had significantly lower systolic blood pressure, total cholesterol and Low-density lipoprotein than GG carriers. People with GG, a homozygote of rs41423247, had a lower body mass index (BMI) and a lower triglyceride than those with the C allele. Although no polymorphism of NR3C1 has been reported on SONFH, the lower risk of blood lipids, systolic blood pressure, and other risk factors for the disease could be studied. In this study, we did not find the relationship between the SNPs allele frequency and genotype frequency of NR3C1 gene and the susceptibility to SONFH, which may be related to the study subjects we selected. The control group we recruited was from the same hospital, but the blood samples of SONFH patients were obtained from different regions and hospitals. It is well known that population confounding is a confounding factor in association analysis, which affects the results of association analysis. Further research is needed to control the interference of regional differences on the research results. Interestingly, this study showed that epigenetic modification of NR3C1 gene can interact with gene polymorphism, providing a new perspective for the pathogenesis of SONFH.

MTHFR is a key enzyme in homocysteine metabolism and folic acid metabolism. It can catalyze 5, 10-Methylenetetrahydrofolate to methylate homocysteine in blood and maintain its level in blood. The rs1801133 polymorphism of the MTHFR gene is caused by a point mutation at position 677, resulting in a decrease in enzyme activity that can cause hyperhomocysteinemia (Zhu et al. 2015). High concentration of homocysteine in the blood will interfere with the function of vascular endothelial cells, resulting in abnormal coagulation and fibrinolysis systems, making the body in a pre-thrombotic state. It can also act on endothelial cells to constrict blood vessels, increase blood pressure, and promote the formation of atherosclerosis. The growth of new blood vessels is the basis of blood supply, and angiogenesis is crucial for wound healing and bone remodeling in most tissues. Therefore, this study included MTHFR as a candidate gene.
A genetic link between ONFH and a tendency to low fibrinolysis or thrombosis has been reported (Gagala et al. 2013). Clotting factors such as MTHFR and plasma plasminogen activation inhibitor -1 (PAI-1) are related to the occurrence of ONFH. Therefore, many studies have proposed that pathogenesis such as coagulation and angiogenesis may also be major risk factors for ONFH. Several case-control studies examined the relationship between the rs1801133 polymorphism of MTHFR gene and ONFH. However, there are inconsistent views on the role of this polymorphisms in the pathogenesis of ONFH, which is also an important factor for us to include rs1801133 in the study. Zalavras et al. (2002) reported a significant statistical difference between the incidence of non-traumatic femoral head necrosis and rs1801133 gene mutation. But there are also some research does not support this result, a south Korean contains 443 ONFH patients and 273 healthy subjects case-control study was carried out on 15 SNPs genetic analysis, found that rs1801133 polymorphism of MTHFR gene and non-traumatic ONFH and no obvious relationship between genetic susceptibility, the author thinks that different regions and ethnic may affect the MTHFR gene polymorphisms between individuals (Kim et al. 2010). Through further research, Shang et al. (2012) conducted a meta-analysis of the association between rs1801133 polymorphism and ONFH, and found in the Asian population cannot find rs1801133 polymorphism and the correlation of ONFH, but can be found in Africa, the crowd and the relative importance of ONFH, suggesting that rs1801133 polymorphism of MTHFR gene may not be a major risk factor for Asian populations ONFH, but a major risk factor for African people ONFH.

When ethnicity was stratified, this meta-analysis provided no evidence of an association between rs1801133 polymorphism and ONFH. Twelve studies were included in the meta-analysis of Chai et al. (2015). The results showed that there was no direct association between ONFH susceptibility and rs1801133 polymorphism. Based on previous studies, we independently analyzed SONFH, hoping to explain the various associations between the MTHFR gene and steroid-induced ONFH reported in the literature. However, our results are also consistent with the results of most studies. We did not find a significant correlation between rs1801133 polymorphism of MTHFR gene and ONFH, and rs1801133 polymorphism may not be an explicit risk factor for thrombosis. Our study did not include an assessment of the mechanisms of hemostasis and, in addition, we did not measure homocysteine levels. The hypothesis that rs1801133 polymorphism may cause SONFH by promoting intravascular coagulation has yet to be confirmed. In addition, in order to study the interaction between SNPs and the methylation level at the site, the methylation level on the CpG island of the MTHFR gene amplicon was detected, and the methylation levels at the site, fragment and gene were statistically analyzed. The results showed that there were statistically significant differences in methylation levels at the sites of MTHFR_1−36, MTHFR_1−77, MTHFR_1-139 and MTHFR_2−42 compared with the control group. In the development of SONFH, epigenetics may be an important bridge connecting the interaction between environmental factors and genes.

Meanwhile, in the current case-control study, we investigated the relationship between rs2453839, rs3110697 of IGFBP3 gene and the risk of ONFH. We confirmed that rs3110697 polymorphism of IGFBP3 gene is related to the occurrence of SONFH in Chinese Han population. Compared with the control group, rs3110697 carriers with A/G genotype had a reduced risk of disease. In the recessive genetic model, the risk of rs3110697 A allele carriers was also reduced. We found that CpG locus IGFBP3_3-143 may interact with IGFBP3 gene polymorphisms, thus affecting the occurrence of SONFH.

IGFBP3 is the main carrier of IGF-1 in blood circulation and can prolong the half-life of IGF-1 in blood circulation. IGF-1 can promote the proliferation of bone cells, increase bone length, participate in the regulation of protein metabolism, induce vitamin D activation (Duchén et al. 2017). IGFBP3 plays a role in hypoxia-induced angiogenesis (Granata et al. 2007). Among IGFBP members, IGFBP3 is the most abundant in the circulatory system and is associated with arteriosclerosis (Jones and Cleemons 1995). Therefore, we believe that IGFBP3 gene polymorphisms may affect blood circulation, damage the femoral head, and further lead to SONFH. Multiple polymorphisms in the IGFBP3 gene are also associated with cancer risk. Previous studies have found a negative association between IGFBP3 rs2453839 and endometrial cancer risk, and a genetic variant of IGFBP3 may influence endometrial cancer risk in Caucasians (Mcgrath et al. 2001). Two IGFBP3 polymorphisms (rs3110697 and rs2854744) were significantly associated with premenopausal women with breast cancer survival (Deming et al. 2007). The relative specificity of IGFBP3 to ONFH has also aroused widespread concern. Jung et al. (2010) used Affymetrix targeted genotyping 3K microarray array to study the SNPs of IGFBP3 gene in 460 patients with ONFH and 300 control subjects. Rs2453839 was significantly associated with alcohol-induced and idiopathic ONFH in a recessive model. Subjects carrying the small homozygous allele CC of rs2453839 had a higher risk of ONFH. Song et al. (2012) reported that IGFBP3 rs2453839 TT and CT frequency of ONFH group increased and decreased compared with normal control group. The association analysis of polymorphism and clinical phenotype showed that the course of disease in patients with IGFBP3 gene rs2453839 TT ONFH was significantly shorter than that in patients with CT + CC. The frequency of CT + CC genotype in stage III / IV bilateral hip lesions group was significantly higher than that in stage III / IV unilateral hip lesions group and stage II / III bilateral hip lesions group. However, we did not find a correlation between rs2453839 polymorphism and SONFH in this statistical analysis. The major models of IGFBP3 gene rs3110697 and rs2453839 were significantly associated with an increased risk of femoral head failure in 182 patients and 179 healthy controls. The genotype of rs2453839 was also associated with clinical stage. Compared with control group, IGF1 in ONFH group increased. Serum triglyceride and Low-density Lipoprotein levels in the ONFH group were significantly higher than those in the control group, but serum high-density Lipoprotein cholesterol levels were significantly lower than those in the control group (Song et al. 2016).
To sum up, our study proved for the first time that epigenetic modifications of NR3C1, MTHFR and IGFBP3 genes can interact with genetic polymorphism to influence SONFH in Chinese Han population. Based on the study of genetic structural characteristics of the disease, we can accurately grasp the development law of the disease. While there are some important findings in our study, there are some limitations. First, our study did not include an analysis of biological function, which is essential to elucidate the role of NR3C1, MTHFR, and IGFBP3 genes in SONFH. Secondly, SONFH needs to be further analyzed by different clinical stages. Thirdly, the control group in our study were all Han recruited from the affiliated hospital of neurology institute of Anhui university of traditional Chinese medicine, which may be a selection bias. Further functional studies and larger case-control studies are expected to avoid these issues and strengthen our conclusions.

**Declarations**

**Acknowledgements**

Grants from the scientific research fund of Anhui University of Chinese Medicine (no. 2018SYLCZ04).

**Author Contributions**

RIH, QHZ, WBH conceived and designed the experiments. RIH, QHZ, RMY, NC, YSH performed the experiments. RIH analyzed the data and wrote the manuscript. All the authors reviewed the manuscript.

**Compliance with ethical standards**

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Ethical approval**

Ethics committee approval was received for this study from the Institute of Neurology of Anhui University of Chinese Medicine.

**References**

1. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP (1995) Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 95:2435-2441. https://doi.org/10.1172/JCI117943

2. Chai W, Zhang Z, Ni M, Gong P, Lian Z, Zhang G, Shi LL, Chen J (2015) Genetic association between methylenetetrahydrofolate reductase gene polymorphism and risk of osteonecrosis of the femoral head. Biomed Res Int 2015:196495. https://doi.org/10.1155/2015/196495

3. Cui L, Zhuang Q, Lin J, Jin J, Zhang K, Cao L, Lin J, Yan S, Guo W, He W, Pei F, Zhou Y, Weng X (2016) Multicentric epidemiologic study on six thousand three hundred and ninety five cases of femoral head osteonecrosis in China. Int Orthop 40:267-76. https://doi.org/10.1007/s00264-015-3061-7

4. Dammann G, Teschler S, Haag T, Altmüller F, Tuczek F, Dammann RH (2011) Increased DNA methylation of neuropsychiatric genes occurs in borderline personality disorder. Epigenetics 6: 1454-1462. https://doi.org/10.4161/epi.6.12.18363

5. Deming SL, Ren Z, Wen W, Shu XO, Cai Q, Gao YT, Zheng W (2007) Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 104: 309-319. https://doi.org/10.1007/s10549-006-9420-8

6. Derijk RH, Schaar MJ, Turner G, Datson NA, Vreugdenhil E, Cidlowski J, de Kloet ER, Emery P, Stemberg EM, Detera-Wadleigh SD (2001) A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J Rheumatol 28:2383-2388.

7. Duchén K, Lindberg A, Kiplok K, Kriström B (2017) Using a spontaneous profile rather than stimulation test makes the KIGS idiopathic growth hormone deficiency model more accessible for clinicians. Acta Paediatr 106: 1481-1486. https://doi.org/10.1111/apa.13932

8. Feng X, Huang D, Lu X, Feng G, Xing J, Lu J, Xu K, Xia W, Meng Y, Tao T, Li L, Gu Z (2014) Insulin-like growth factor 1 can promote proliferation and osteogenic differentiation of human dental pulp stem cells via mTOR pathway. Dev Growth Differ 56: 615-624. https://doi.org/10.1111/dgd.12179

9. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluivtmans LA, van der Heuvel LP (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113. https://doi.org/10.1038/ng0595-111
31. Ukkola O, Pérusse L, Chagnon YC, Després JP, Bouchard C (2001) Interactions among the glucocorticoid receptor, lipoprotein lipase and adrenergic receptor genes and abdominal fat in the Québec Family Study. Int J Obes Relat Metab Disord 25: 1332-1339. https://doi.org/10.1038/sj.ijo.0801735

32. van Rossum EF, Koper JW, van den Beld AW, Uitterlinden AG, Arp P, Ester W, Janssen JA, Brinkmann AO, de Jong FH, Grobbee DE, Pols HA, Lamberts SW (2003) Identification of the Bcll polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol (Oxf). 59: 585-592. https://doi.org/10.1046/j.1365-2265.2003.01888.x

33. van Rossum EF, Lamberts SW (2004) Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 59: 333-357. https://doi.org/10.1210/rp.59.1.333

34. Wan E S (2018) Examining genetic susceptibility in acute exacerbations of COPD. Thorax 73: 507-509. https://doi.org/10.1136/thoraxjnl-2017-211106

35. Wang L, Yang B, Zhou S, Gao H, Wang F, Zhou J, Wang H, Wang Y (2018) Risk factors and methylenetetrahydrofolate reductase gene in congenital heart disease. J Thorac Dis 10: 441-447. https://doi.org/10.21037/jtd.2017.12.08

36. Werner A, Jäger M, Schmitz H, Krauspe R (2003) Joint preserving surgery for osteonecrosis and osteochondral defects after chemotherapy in childhood. Klin Padiatr 215: 332-337. https://doi.org/10.1055/s-2003-45495

37. Yan YX, Dong J, Wu LJ, Shao S, Zhang J, Zhang L, Wang W, He Y, Liu YQ (2013) Associations between polymorphisms in the glucocorticoid-receptor gene and cardiovascular risk factors in a Chinese population. J Epidemiol 23: 389-395. https://doi.org/10.2188/jea.je20130035

38. Yehuda R, Daskalakis NP, Lehrner A, Desarnaud F, Bader HN, Makotkine I, Flory JD, Bierer LM, Meaney MJ (2014) Influences of maternal and paternal PTSD on epigenetic regulation of the glucocorticoid receptor gene in Holocaust survivor offspring. Am J Psychiatry 171: 872-880. https://doi.org/10.1176/appi.ajp.2014.13121571

39. Zalavras CG, Malizos KN, Dokou E, Vartholomatos G (2002) The 677C-->T mutation of the methylene-tetrahydrofolate reductase gene in the pathogenesis of osteonecrosis of the femoral head. Haematologica 87: 111-112.

40. Zhu XY, Hou RY, Pan XD, Wang YC, Zhang ZS, Guo RY (2015) Association between the methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism and ischemic stroke in the Chinese population: a meta-analysis. Int J Neurosci 125: 885-894. https://doi.org/10.3109/00207454.2014.984295